Clinical manifestations of granulomatosis with polyangiitis: key considerations and major features

References

• Jennette JC, Falk RJ, Bacon PA, et al. 2012. Revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum 2013; 65:1–11.
   Google Scholar
• Gómez-Gómez A, Martínez-Martínez MU, Cuevas-Orta E, et al. Pulmonary manifestations of granulomatosis with polyangiitis. Reumatología Clínica. 2014;10:288–293.
   PubMedGoogle Scholar
• McGeoch L, Carette S, Cuthbertson D, et al. Cardiac involvement in granulomatosis with polyangiitis. J Rheumatol. 2015;42:1209–1212.
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhou G, Shi Q, et al. Clinical analysis of nervous system involvement in ANCA-associated systemic vasculitides. Clin Exp Rheumatol. 2009;27:S65–S69.
   PubMed Web of Science ®Google Scholar
• Genius K, Pewarchuk J. Granulomatosis with polyangiitis (Wegener’s) as a necrotizing gingivitis mimic: a case report. J Med Case Rep. 2014;8:297.
   PubMedGoogle Scholar
• Carter LM, Brizman E. Lingual infarction in Wegener’s granulomatosis: a case report and review of the literature. Head Face Med. 2009;4:19.
   Google Scholar
• Catanoso M, Macchioni P, Boiardi L, et al. Epidemiology of granulomatosis with polyangiitis (Wegener ׳s granulomatosis) in northern Italy: a 15-year population-based study. Semin Arthritis Rheum. 2014;44:202–207.
   PubMed Web of Science ®Google Scholar
• Watts RA, Mooney J, Skinner J, et al. The contrasting epidemiology of granulomatosis with polyangiitis (Wegener’s) and microscopic polyangiitis. Rheumatology (Oxford). 2012;51:926–931.
   PubMed Web of Science ®Google Scholar
• Jokar M, Mirfeizi Z. Epidemiology of vasculitides in Khorasan province, Iran. Iran J Med Sci. 2015;40:362–366.
   PubMed Web of Science ®Google Scholar
• Holle JU, Gross WL, Latza U, et al. Improved outcome in 445 patients with Wegener’s granulomatosis in a German vasculitis center over four decades. Arthritis Rheum. 2011;63:257–266.
   PubMed Web of Science ®Google Scholar
• Mohammad AJ, Jacobsson LTH, Westman KWA, et al. Incidence and survival rates in Wegener’s granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. Rheumatology (Oxford). 2009;48:1560–1565.
   PubMed Web of Science ®Google Scholar
• Mohammad AJ, Jacobsson LTH, Mahr AD, et al. Prevalence of Wegener’s granulomatosis, microscopic polyangiitis, polyarteritis nodosa and churg-strauss syndrome within a defined population in southern sweden. Rheumatology (Oxfrod). 2007;46:1329–1337.
   PubMed Web of Science ®Google Scholar
• Gomes GL, Halpern AS, Souza FH, et al. Association between saddle nose deformity and retro-orbital mass in Wegener’s granulomatosis. Acta Reumatol Port. 2010;35:340–345.
   PubMed Web of Science ®Google Scholar
• Chen YX, Yu HJ, Zhang W, et al. Analyzing fatal cases of Chinese patients with primary antineutrophil cytoplasmic antibodies-associated renal vasculitis: a 10-year retrospective study. Kidney Blood Press Res. 2008;31:343–349.
   PubMed Web of Science ®Google Scholar
• Kapoor E, Cartin-Ceba R, Specks U, et al. Pituitary dysfunction in granulomatosis with polyangiitis: the mayo clinic experience. J Clin Endocrinol Metab. 2014;99:3988–3994.
   PubMed Web of Science ®Google Scholar
• Iudici M, Quartier P, Terrier B, et al. Childhood-onset granulomatosis with polyangiitis and microscopic polyangiitis: systematic review and meta-analysis. Orphanet J Rare Dis. 2016;11:141.
   PubMed Web of Science ®Google Scholar
• Katsuyama T, Sada KE, Makino H. Current concept and epidemiology of systemic vasculitides. AllergolInt. 2014;63:505–513.
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Fujimoto S. Epidemiology of vasculitides: differences between Japan, Europe and North America. Clin Exp Nephrol. 2013;17:611–614.
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Fujimoto S, Takahashi K, et al. Anti-neutrophil cytoplasmic antibody associated vasculitis, large vessel vasculitis and Kawasaki disease in Japan. Kidney Blood Press Res. 2010;33:442–455.
   PubMed Web of Science ®Google Scholar
• Cartin-Ceba R, Peikert T, Specks U. Pathogenesis of ANCA-associated vasculitis. Rheum Dis Clin North Am. 2010;36:463–477.
   PubMed Web of Science ®Google Scholar
• Xie G, Roshandel D, Sherva R, et al. Association of granulomatosis with polyangiitis (Wegener’s) with HLA–DPB1*04 and SEMA6A gene variants evidence from genomewide analysis. Arthritis Rheum. 2013;65:2457–2468.
   PubMed Web of Science ®Google Scholar
• Mahr AD, Edberg JC, Stone JH, et al. Alpha1-antitrypsin deficiency–related alleles Z and S and the risk of Wegener’s granulomatosis. Arthritis Rheum. 2010;62:3760–3767.
   PubMed Web of Science ®Google Scholar
• Pervakova MY, Emanuel VL, Titova ON, et al. The diagnostic value of alpha-1-antitrypsin phenotype in patients with granulomatosis with polyangiitis. Int J Rheumatol 2016; 2016:7831410.
   PubMedGoogle Scholar
• Chung SA, Xie G, Roshandel D, et al. Meta-analysis of genetic polymorphisms in granulomatosis with polyangiitis (Wegeners) reveals shared susceptibility loci with rheumatoid arthritis. Arthritis Rheum. 2012;64:3463–3471.
   PubMed Web of Science ®Google Scholar
• Lee YH, Choi SJ, Ji JD, et al. CTLA-4 and TNF-α promoter-308 A/G polymorphisms and ANCA-associated vasculitis susceptibility: a meta-analysis. Mol Biol Rep. 2012;39:319–326.
   PubMed Web of Science ®Google Scholar
• Lyons PA, Rayner TF, Trivedi S, et al. Genetically distinct subsets within ANCA associated vasculitis. N Engl J Med. 2012;367:214–223.
   PubMed Web of Science ®Google Scholar
• Kerstein A, SchüLer S, Cabral-Marques O, et al. Environmental factor and inflammation driven alteration of the total peripheral T-cell compartment in granulomatosis with polyangiitis. J Autoimmun. 2017;78:79–91.
   PubMed Web of Science ®Google Scholar
• Abdulahad WH, Lamprecht P, Kallenberg CG. T-helper cells as new players in ANCA associated vasculitides. Arthritis Res Ther. 2011;13:236.
   PubMed Web of Science ®Google Scholar
• Kelley JM, Edberg JC, Kimberly RP. Wegener’s granulomatosis: a model of autoantibodies in mucosal autoimmunity. Clin Immunol. 2010;134:104–112.
   PubMed Web of Science ®Google Scholar
• Kallenberg CGM. Pathophysiology of ANCA-associated small vessel vasculitis. Curr Rheumatol Rep. 2010;12:399–405.
   PubMedGoogle Scholar
• Schönermarck U, Csernok E, Gross WL. Pathogenesis of anti-neutrophil cytoplasmic antibody-associated vasculitis: challenges and solutions 2014. Nephrol Dial Transplant. 2015;30:i46–i52.
   PubMed Web of Science ®Google Scholar
• Stone JH. Limited versus severe Wegener’s granulomatosis: baseline data on patients in the Wegener’s granulomatosis etanercept trial. Arthritis Rheum. 2003;48:2299–2309.
   PubMed Web of Science ®Google Scholar
• Finkielman JD, Lee AS, Hummel AM, et al. ANCA are detectable in nearly all patients with active severe Wegener’s granulomatosis. Am J Med. 2007;120(7):643.e9–14.
   PubMed Web of Science ®Google Scholar
• Sanders JS, Huitma MG, Kallenberg CG, et al. Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment. Rheumatology (Oxford). 2006;45(6):724–729.
   PubMed Web of Science ®Google Scholar
• Flossmann O, Berden A, de Groot K, et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis. 2011;70(3):488–494.
   PubMed Web of Science ®Google Scholar
• Hogan SL, Falk RJ, Chin H, et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med. 2005;143(9):621–631.
   PubMed Web of Science ®Google Scholar
• Lionaki S, Blyth ER, Hogan SL, et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum. 2012;64(10):3452–3462.
   PubMed Web of Science ®Google Scholar
• Kronbichler A, Kerschbaum J, Mayer G. The influence and role of microbial factors in autoimmune kidney diseases: a systematic review. J Immuno Res. 2015;2015:858027.
   PubMed Web of Science ®Google Scholar
• Stamp LK, Chapman PT, Francis J, et al. Association between environmental exposures and granulomatosis with polyangiitis in Canterbury, New Zealand. Arthritis Res Ther. 2015;17:333.
   PubMed Web of Science ®Google Scholar
• Gatenby PA, Lucas RM, Engelsen O, et al. Antineutrophil cytoplasmic antibody-associated vasculitides: could geographic patterns be explained by ambient ultraviolet radiation? Arthritis Rheum. 2009;61:1417–1424.
   PubMed Web of Science ®Google Scholar
• Gao Y, Zhao MH. Review article: drug-induced anti-neutrophil cytoplasmic antibody associated vasculitis. Nephrology (Carlton). 2009;14:33–41.
   PubMed Web of Science ®Google Scholar
• Kubaisi B, Abu Samra K, Foster CS. Granulomatosis with polyangiitis (Wegener’s disease): an updated review of ocular disease manifestations. Intractable Rare Dis Res. 2016;5:61–69.
   PubMed Web of Science ®Google Scholar
• Schirmer JH, Wright MN, Herrmann K, et al. Myeloperoxidase–antineutrophil cytoplasmic antibody (ANCA)-positive granulomatosis with polyangiitis (Wegener’s) is a clinically distinct subset of ANCA-associated vasculitis: a retrospective analysis of 315 patients from a German vasculitis referral center. Arthritis Rheumatol. 2016;68:2953–2963.
   PubMed Web of Science ®Google Scholar
• Cabral DA, Uribe AG, Benseler S, et al. Classification, presentation, and initial treatment of Wegener’s granulomatosis in childhood. Arthritis Rheum. 2009;60:3413–3424.
   PubMed Web of Science ®Google Scholar
• Akikusa JD, Schneider R, Harvey EA, et al. Clinical features and outcome of pediatric Wegener’s granulomatosis. Arthritis Rheum. 2007;57:837–844.
   PubMed Web of Science ®Google Scholar
• Morales-Angulo C, García-Zornoza R, Obeso-Agüera S, et al. Ear, nose and throat manifestations of Wegener’s granulomatosis (granulomatosis with polyangiitis). Acta Otorrinolaringol Esp. 2012;63:206–211.
   PubMedGoogle Scholar
• Cannady SB, Batra PS, Koening C, et al. Sinonasal Wegener granulomatosis: a single institution experience with 120 cases. Laryngoscope. 2009;119:757–761.
   PubMed Web of Science ®Google Scholar
• Magrey MN, Villa-Forte A, Koening CL, et al. Persistent hematuria after induction of remission in Wegener granulomatosis: a therapeutic dilemma. Medicine (Baltimore). 2009;88:315–321.
   PubMed Web of Science ®Google Scholar
• Binda V, Moroni G, Messa P. ANCA-associated vasculitis with renal involvement. J Nephrol. 2018;31(2):197–208.
   PubMed Web of Science ®Google Scholar
• Zycinska K, Wardyn KA, Tyszko P, et al. Analysis of early death based on the prediction model in Wegener’s granulomatosis with pulmonary and renal involvement. J Physiol Pharmacol. 2007;58:829–837.
   PubMed Web of Science ®Google Scholar
• Solans-Laqué R, Fraile G, Rodriguez-Carballeira M, et al. Clinical characteristics and outcome of Spanish patients with ANCA-associated vasculitides. Medicine (Baltimore). 2017;96(8):e6083.
   PubMed Web of Science ®Google Scholar
• De Parisot A, Puéchal X, Langrand C, et al. Pituitary involvement in granulomatosis with polyangiitis: report of 9 patients and review of the literature. Medicine (Baltimore). 2015;94(16):e748.
   PubMed Web of Science ®Google Scholar
• Lutalo PM, D’Cruz DP. Diagnosis and classification of granulomatosis with polyangiitis (aka Wegener’s granulomatosis). J Autoimmun. 2014;48:94–98.
   PubMed Web of Science ®Google Scholar
• Feragalli B, Mantini C, Sperandeo M, et al. The lung in systemic vasculitis: radiological patterns and differential diagnosis. Br J Radiol. 2016;89(1061):20150992.
   PubMed Web of Science ®Google Scholar
• Watts R, Lane S, Hanslik T, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007;66:222–227.
   PubMed Web of Science ®Google Scholar
• Liu LJ, Chen M, Yu F, et al. Evaluation of a new algorithm in classification of systemic vasculitis. Rheumatology. 2008;47:708–712.
   PubMed Web of Science ®Google Scholar
• Mukhtyar C, Lee R, Brown D, et al. Modification and validation of the Birmingham vasculitis activity score (version 3). Ann Rheum Dis. 2009;68:1827–1832.
   PubMed Web of Science ®Google Scholar
• Almouhawis HA, Leao JC, Fedele S, et al. Wegener’s granulomatosis: a review of clinical features and an update in diagnosis and treatment. J Oral Pathol Med. 2013;42:507−516.
   PubMed Web of Science ®Google Scholar
• Csernok E, Lamprecht P, Gross WL. Clinical and immunological features of drug induced and infection-induced proteinase 3-antineutrophil cytoplasmic antibodies and myeloperoxidase-antineutrophil cytoplasmic antibodies and vasculitis. Curr Opin Rheumatol. 2010;22:43–48.
   PubMed Web of Science ®Google Scholar
• Stahelin L, Fialho SCDMS, Neves FS, et al. Cocaine-induced midline destruction lesions with positive ANCA test mimicking Wegener’s granulomatosis. Rev Bras Reumatol. 2012;52:434–437.
   Web of Science ®Google Scholar
• Mahmood FS, Schwatz E, Kurrup S, et al. A diagnostic dilemma: differentiating between granulomatosis with polyangiitis and tuberculosis. Clin Med (Lond). 2013;13:411–413.
   PubMed Web of Science ®Google Scholar
• Pakalniskis MG, Berg AD, Policeni BA, et al. The many faces of granulomatosis with polyangiitis: a review of the head and neck imaging manifestations. AJR Am J Roentgenol. 2015;205:W619–W629.
   PubMed Web of Science ®Google Scholar
• Stratta P, Marcuccio C, Campo A, et al. Improvement in relative survival of patients with vasculitis: study of 101 cases compared to the general population. Int J Immunopathol Pharmacol. 2008;21:631–642.
   PubMed Web of Science ®Google Scholar
• Dadoniene J, Pileckyte M, Baranauskaite A, et al. Clinical characteristics and long-term outcomes of 35 patients with Wegener’s granulomatosis followed up at two rheumatology centers in Lithuania. Medicina (Kaunas). 2010;46:256–260.
   PubMed Web of Science ®Google Scholar
• Wu CS, Hsieh CJ, Peng YS, et al. Antineutrophil cytoplasmic antibody-associated vasculitis in Taiwan: a hospital-based study with reference to the population-based national health insurance database. J Microbiol Immunol Infect. 2015;48:477–482.
   PubMedGoogle Scholar
• Sen N, Aydin Tufan M, Yildiz R, et al. Granulomatous polyangitis (Wegener granulomatosis): clinical findings and results of long-term follow-up. Tuberk Toraks. 2016;64:223–229.
   PubMed Web of Science ®Google Scholar
• Sharma A, Naidu GSRSNK, Rathi M, et al. Clinical features and long-term outcomes of 105 granulomatosis with polyangiitis patients: a single center experience from north India. Int J Rheum Dis. 2018;21(1):278–284.
   Web of Science ®Google Scholar
• Antoniu SA. Treatment options for refractory Wegener’s granulomatosis: a role for rituximab? Curr Opin Investig Drugs. 2007;8:927–932.
   PubMed Web of Science ®Google Scholar
• Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75:1583–1594.
   PubMed Web of Science ®Google Scholar
• Wolter NE, Ooi EH, Witterick IJ. Intralesional corticosteroid injection and dilatation provides effective management of subglottic stenosis in Wegener’s granulomatosis. Laryngoscope. 2010;120:2452–2455.
   PubMed Web of Science ®Google Scholar
• Wung PK, Anderson T, Fontaine KR, et al. Effects of glucocorticoids on weight change during the treatment of Wegener’s granulomatosis. Arthritis Rheum. 2008;59:746–753.
   PubMed Web of Science ®Google Scholar
• Ahmed SV, Chandra S. Widespread cranial nerve palsies while on cyclophosphamide therapy: a very rare manifestation of Wegener’s granulomatosis (granulomatosis with polyangitis). BMJ Case Rep. 2013; 2013:bcr2013200547.
   Google Scholar
• Osuna A, Garrido J. Cyclophosphamide-intolerant Wegener’s granulomatosis successfully treated with mycophenolate mofetil. ActaReumatol Port. 2008;33:224–228.
   Google Scholar
• De Menthon M, Cohen P, Pagnoux C, et al. Infliximab or rituximab for refractory Wegener’s granulomatosis: long-term follow up. A prospective randomized multicentre study on 17 patients. Clin Exp Rheumatol. 2011;29:S63–S71.
   PubMed Web of Science ®Google Scholar
• Clowse ME, Copland SC, Hsieh TC, et al. Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener’s). Arthritis Care Res (Hoboken). 2011;63:1777–1781.
   PubMed Web of Science ®Google Scholar
• Pagnoux C, Quéméneur T, Ninet J, et al. Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy. Arthritis Rheumatol. 2015;67(4):1117–1127.
   PubMed Web of Science ®Google Scholar
• Faurschou M, Mellemkjaer L, Voss A, et al. Prolonged risk of specific malignancies following cyclophosphamide therapy among patients with granulomatosis with polyangiitis. Rheumatology (Oxford). 2015;54:1345–1350.
   PubMed Web of Science ®Google Scholar
• Faurschou M, Sorensen IJ, Mellemkjaer L, et al. Malignancies in Wegener’s granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol. 2008;35:100–105.
   PubMed Web of Science ®Google Scholar
• Lynch JP, Tazelaar H. Wegener granulomatosis (granulomatosis with polyangiitis): evolving concepts in treatment. Semin Respir Crit Care Med. 2011;32:274–297.
   PubMed Web of Science ®Google Scholar
• Henes JC, Fritz J, Koch S, et al. Rituximab for treatment-resistant extensive wegener’s granulomatosis–additive effects of a maintenance treatment with leflunomide. Clin Rheumatol. 2007;26:1711–1715.
   PubMed Web of Science ®Google Scholar
• Brihaye B, Aouba A, Pagnoux C, et al. Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener’s granulomatosis: a study on 8 patients. Clin Exp Rheumatol. 2007;25:S23–27.
   PubMed Web of Science ®Google Scholar
• Calich AL, Puéchal X, Pugnet G, et al. Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener’s). Results of a single-center cohort study on 66 patients. J Autoimmun. 2014;50:135–141.
   PubMed Web of Science ®Google Scholar
• Seo P, Specks U, Keogh KA. Efficacy of rituximab in limited Wegener’s granulomatosis with refractory granulomatous manifestations. J Rheumatol. 2008;35:2017–2023.
   PubMed Web of Science ®Google Scholar
• Wawrzycka-Adamczyk K, Zugaj A, Włudarczyk A, et al. Lower doses of rituximab in remission induction for refractory granulomatosis with polyangiitis. PrzeglLek. 2014;71:663–665.
   Google Scholar
• Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371(19):1771–1780.
   PubMed Web of Science ®Google Scholar
• Holle JU, Dubrau C, Herlyn K, et al. Rituximab for refractory granulomatosis with polyangiitis (Wegener’s granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann Rheum Dis. 2012;71:327–333.
   PubMed Web of Science ®Google Scholar
• Henderson SR, Copley SJ, Pusey CD, et al., 1Prolonged B cell depletion with rituximab is effective in treating refractory pulmonary granulomatous inflammation in granulomatosis with polyangiitis (GPA). Medicine (Baltimore) 2014:93(27):e229.
   Web of Science ®Google Scholar
• Lally L, Lebovics RS, Huang WT, et al. Effectiveness of rituximab for the otolaryngologic manifestations of granulomatosis with polyangiitis (wegener’s). Arthritis Care Res (Hoboken). 2014;66:1403–1409.
   PubMed Web of Science ®Google Scholar
• Besada E, Koldingsnes W, Nossent JC. Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre. Rheumatology (Oxford). 2013;52:2041–2047.
   PubMed Web of Science ®Google Scholar
• Knight A, Hallenberg H, Baecklund E. Efficacy and safety of rituximab as maintenance therapy for relapsing granulomatosis with polyangiitis – a case series. Clin Rheumatol. 2014;33:841–848.
   PubMed Web of Science ®Google Scholar
• Cartin-Ceba R, Golbin JM, Keogh KA, et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener’s): ten-year experience at a single center. Arthritis Rheum. 2012;64:3770–3778.
   PubMed Web of Science ®Google Scholar
• Hiemstra TF, Walsh M, Mahr A, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA. 2010;304:2381–2388.
   PubMed Web of Science ®Google Scholar
• Bremer JP, Ullrich S, Laudien M, et al. Methotrexate plus leflunomide for the treatment of relapsing Wegener’s granulomatosis. A retrospective uncontrolled study. . Clin Exp Rheumatol. 2010;28:67–71.
   PubMed Web of Science ®Google Scholar
• Villa-Forte A, Clark TM, Gomes M, et al. Substitution of methotrexate for cyclophosphamide in Wegener granulomatosis: a 12-year single-practice experience. Medicine (Baltimore). 2007;86:269–277.
   PubMed Web of Science ®Google Scholar
• Langford CA, Monach PA, Specks U, et al. An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener’s). Ann Rheum Dis. 2014;73:1376–1379.
   PubMed Web of Science ®Google Scholar
• Silva F, Seo P, Schroeder DR, et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s): long-term follow-up of a multicenter longitudinal cohort. Arthritis Rheum. 2011;63:2495–2503.
   PubMed Web of Science ®Google Scholar
• Flossmann O, Baslund B, Bruchfeld A, et al. Deoxyspergualin in relapsing and refractory Wegener’s granulomatosis. Ann Rheum Dis. 2009;68:1125–1130.
   PubMed Web of Science ®Google Scholar
• Guidelli GM, Tenti S, Pascarelli NA, et al. Granulomatosis with polyangiitis and intravenous immunoglobulins: a case series and review of the literature. Autoimmun Rev. 2015;14:659–664.
   PubMed Web of Science ®Google Scholar
• Fortin PM, Tejani AM, Bassett K, et al. Intravenous immunoglobulin as adjuvant therapy for Wegener’s granulomatosis. Cochrane Database Syst Rev. 2009;8:CD007057.
   Google Scholar
• Grygiel-Górniak B, Puszczewicz M. Granulomatosis with polyangiitis in pregnancy – clinical implications and treatment possibilities. Eur Rev Med PharmacolSci. 2015;19:2331–2335.
   PubMed Web of Science ®Google Scholar
• Walsh M, Chaudhry A, Jayne D. Long-term follow-up of relapsing/refractory antineutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Ann Rheum Dis. 2008;67(9):1322–1327.
   Google Scholar
• Jayne DRW, Bruchfeld AN, Harper L, et al. Trial of C5A receptor inhibitor avacopan in ANCA-associated vasculitis. J Am SocNephrol. 2017;28(9):2756–2767.
   Web of Science ®Google Scholar
• Walsh M, Merkel P, Peh C, et al. Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. Trials. 2013;14:73.
   PubMed Web of Science ®Google Scholar
• Szpirt WM, Heaf JG, Petersen J. Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener’s granulomatosis-a clinical randomized controlled trial. Nephrol Dial Transplant. 2011;26:206–213.
   PubMed Web of Science ®Google Scholar
• Szpirt WM. Plasma exchange in antineutrophil cytoplasmic antibody-associated vasculitis–a 25-year perspective. Nephrol Dial Transplant. 2015;30:146–149.
   Web of Science ®Google Scholar
• Walsh M, Casian A, Flossmann O, et al. Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int. 2013;84(2):397–402.
   Web of Science ®Google Scholar
• Merkel P. Plasma exchange and glucocorticoids for treatment of anti-neutrophil cytoplasm antibody (ANCA) – associated vasculitis (PEXIVAS). Cited: https://clinicaltrials.gov/ct2/show/NCT00987389. NLM identifier: NCT00987389. Accessed July 10, 2018.
   Google Scholar
• Springer J, Nutter B, Langford CA, et al. Granulomatosis with polyangiitis (Wegener’s): impact of maintenance therapy duration. Medicine (Baltimore). 2014;93:82–90.
   PubMed Web of Science ®Google Scholar
• Pugnet G, Pagnoux C, Bézanahary H, et al. Progressive multifocal encephalopathy after cyclophosphamide in granulomatosis with polyangiitis(Wegener) patients: case report and review of literature. ClinExpRheumatol. 2013;31:S62–S64.
   Web of Science ®Google Scholar
• Roubaud-Baudron C, Pagnoux C, Méaux-Ruault N, et al. Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. J Rheumatol. 2012;39:125–130.
   PubMed Web of Science ®Google Scholar
• Zycinska K, Wardyn KA, Zielonka TM, et al. Co-trimoxazole and prevention of relapses of PR3-ANCA positive vasculitis with pulmonary involvement. Eur J Med Res. 2009;14:265–267.
   PubMed Web of Science ®Google Scholar
• Kallenberg CG. What is the evidence for prophylactic antibiotic treatment in patients with systemic vasculitides?. Curr Opin Rheumatol. 2011;23(3):311–316.
   PubMed Web of Science ®Google Scholar
• Emmi G, Silvestri E, Squatrito D, et al. Thrombosis in vasculitis: from pathogenesis to treatment. Thromb J. 2015;13:15.
   PubMed Web of Science ®Google Scholar
• Faurschou M, Obel N, Baslund B, et al. High risk of pulmonary embolism and deep venous thrombosis but not of stroke in granulomatosis with polyangiitis (Wegener’s). Arthritis Care Res (Hoboken). 2014;66(12):1910–1914.
   PubMed Web of Science ®Google Scholar
• Karimifar M. Deep vein thrombosis in combination with granulomatosis with polyangiitis (Wegener’s). J Nephropathol. 2012 Apr;1(1):57–58.
   PubMedGoogle Scholar
• Liu XX, Zhu XM, Miao Q, et al. Hyperglycemia induced by glucocorticoids in nondiabetic patients: a meta-analysis. Ann Nutr Metab. 2014;65(4):324–332.
   PubMed Web of Science ®Google Scholar
• Nakajima A, Doki K, Homma M, et al. Investigation of glucocorticoid-induced side effects in patients with autoimmune diseases. Yakugaku Zasshi. 2009;129(4):445–450.
   PubMed Web of Science ®Google Scholar